10,366 Shares in AnaptysBio, Inc. $ANAB Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,366 shares of the biotechnology company’s stock, valued at approximately $700,000.

Several other large investors have also recently added to or reduced their stakes in ANAB. Group One Trading LLC purchased a new stake in AnaptysBio in the 2nd quarter worth approximately $140,000. Cibc World Market Inc. purchased a new position in shares of AnaptysBio during the 2nd quarter valued at $587,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of AnaptysBio during the 2nd quarter valued at $9,519,000. Clear Harbor Asset Management LLC acquired a new position in shares of AnaptysBio in the second quarter worth $780,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of AnaptysBio in the second quarter worth $208,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on ANAB. Wolfe Research reissued an “outperform” rating and set a $78.00 price objective on shares of AnaptysBio in a research report on Monday, August 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a report on Monday, August 24th. Finally, TD Cowen lowered their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Eleven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus target price of $79.85.

AnaptysBio Trading Down 1.1%

AnaptysBio stock opened at $56.80 on Friday. AnaptysBio, Inc. has a 1-year low of $11.40 and a 1-year high of $72.36. The firm’s fifty day simple moving average is $58.18 and its 200-day simple moving average is $59.19. The company has a market capitalization of $1.68 billion, a P/E ratio of -52.59 and a beta of 0.71.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.